Litcius/Paper detail

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

Keith S. Kaye, Andrew F. Shorr, Richard G. Wunderink, Bin Du, Gabrielle Poirier, Khurram Rana, Alita A. Miller, Drew Lewis, John P. O’Donnell, Lan Chen, Harald H. Reinhart, Subasree Srinivasan, Robin Isaacs, David Altarac

2023The Lancet Infectious Diseases287 citationsDOI

Topics & Concepts

MedicineColistinSulbactamInternal medicineAcinetobacter baumanniiImipenem/cilastatinPopulationCarbapenemAcinetobacterPneumoniaImipenemClinical endpointVentilator-associated pneumoniaAntibioticsRandomized controlled trialMicrobiologyAntibiotic resistancePseudomonas aeruginosaBiologyGeneticsBacteriaEnvironmental healthAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyAntibiotic Use and Resistance
Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) | Litcius